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Introduction. In Japan, the cost-eﬀectiveness of total colonoscopy (TCS) for primary screening of colorectal cancer (CRC) is
unclear. We compared the cost of identifying a patient with CRC using two primary screening strategies: TCS (strategy 1) and the
immunochemical fecal test (FIT) (strategy 2). Materials and Methods. We retrospectively analyzed the TCS screening database at
our institution from February 2004 to August 2010 (strategy 1, n = 15,348) and the Japanese nationwide survey of CRC screening
in 2008 (strategy 2, n = 5,267,443). Results. 112 and 6,838CRC cases were detected in strategies 1 and 2, costing 2,124,000JPY
and 1,629,000JPY, respectively. The rate of earlier-stage CRC was higher in strategy 1. Conclusions. The cost was higher using TCS
as a primary screening procedure. However, the diﬀerence was not excessive, and considering the increased rate of detecting earlier
CRC, the use of TCS as a primary screening tool may be cost-eﬀective.
1.Introduction
In Japan, the incidence and mortality rate of colorectal can-
cer (CRC) has increased signiﬁcantly, with an incidence of
approximately 100,000 cases and over 40,000 deaths per year
[1]. CRC is now the second most commonly diagnosed can-
cer and the third leading cause of cancer-related mortality
in Japan. In order to decrease the incidence and mortality of
CRC, a screening system has been established. There are two
types of CRC screening in Japan; one is population-based
screening recommended for the entire population aging 40
and over, and the other is opportunistic screening. In popu-
lation-based screening, the immunochemical fecal test (FIT)
is used as a primary screening tool and total colonoscopy
(TCS) is only performed for those with a positive FIT. TCS
is not used as a primary screening procedure in population-
based screening. On the other hand, in opportunistic screen-
ing, TCS is widely used as a primary screening procedure.
Inthissituation,therelativecost-eﬀectivenessofdiﬀerent
CRC screening strategies needs to be clariﬁed. Such analyses
havebeenperformedintheUnitedStatesandothercountries
[2–8], but in Japan, there have been limited analyses of the
cost-eﬀectiveness of CRC screening [9, 10], with the stud-
ies available demonstrating the population-based screening
strategytobecost-eﬀective.Incontrast,thecost-eﬀectiveness
of TCS as a primary screening strategy in opportunistic
screening is still unclear.
In this study, our primary objective was to compare the
cost of identifying a patient with CRC in Japan using two
strategies: TCS as a ﬁrst screen (strategy 1) versus FIT as a
ﬁrst screen (strategy 2).
2.MaterialsandMethods
We retrospectively analyzed the cost of identifying a patient
with CRC using strategies 1 and 2 as follows.
2.1.Strategy1:TCSasaPrimaryScreening. We retrospective-
ly reviewed the database of the Cancer Screening Division,2 Gastroenterology Research and Practice
Research Center for Cancer Prevention and Screening, Na-
tional Cancer Center, which followed all subjects given a TCS
as a primary screening from February 2004 to August 2010.
A total of 15,348 cases had a colonoscopy performed as a pri-
mary screening. This data was used to calculate the cost as-
sociated with identifying a patient with CRC using the cost
of TCS as 15,500 JPY, based on Japanese national reimburse-
ment tables.
2.2. Strategy 2: FIT as a Primary Screening. We retrospective-
ly analyzed the Japanese nationwide survey of CRC screening
in 2008 [11]. A total of 5,267,443 cases were included. This
datawasusedtocalculatethecostassociatedwithidentifying
a patient with CRC using the cost of FIT as 1,600 JPY and
TCS as 15,500 JPY, respectively.
3. Results
Clinical characteristics of examinees in strategies 1 and 2 are
listed in Table 1. Both groups predominantly comprised ex-
aminees in their 50s and 60s, and there was a higher male-to-
female ratio in strategy 2 than in strategy 1. However, there
was no statistical signiﬁcance between two groups.
The number of CRC cases identiﬁed and the cost to ﬁnd
one case of CRC in both groups are listed in Table 2.I ns t r a t -
egy 1, there were 112 cases of CRC among 15,348 TCS exam-
inees (0.73%), with a calculated cost of ﬁnding one CRC case
of 2,124,000 JPY. In group 2, 5,267,443 underwent FIT, with
319,846 cases testing positive, (6.1%). All examinees with a
positive FIT were recommended for a further TCS. However,
only 174,914 examinees (54.7%) underwent TCS, and 6,838
cases of CRC were found. The calculated cost to ﬁnd one pa-
tient with CRC was 1,629,000 JPY in this group. If all of the
319,846 cases with a positive FIT had undergone TCS, the
number of CRC cases would have increased, reducing the
cost of identifying CRC. Assuming that the rate of CRC cases
among the TCS examinees was the same as that in the stra-
tegy 2 group (3.9%; 6,838/174,914), it was calculated that
there would be 12,504 CRC patients, each costing 1,090,000
JPY to be identiﬁed.
The staging of CRC at diagnosis (Japanese Classiﬁcation
of Colorectal Carcinoma) and initial treatment for CRC are
summarized in Table 2. The rate of stage 0 and endoscopic
resection were higher in strategy 1 than in strategy 2.
4. Discussion
Several previous studies have shown that CRC screening in-
cluding FIT and TCS is cost-eﬀe c t i v e .H o w e v e r ,i nJ a p a n ,
onlyafewcost-eﬀectiveanalyseshavebeenreported,withthe
cost-eﬀectiveness of TCS as primary screening still unclear.
In this analysis, we compared the cost of identifying a pa-
tient with CRC using two screening strategies, using TCS as a
primary screening, or using FIT as a primary screening with
TCS then performed in cases with a positive FIT test. The
results demonstrated that it cost more to identify CRC when
TCS was used as a primary screening strategy compared to
the FIT screening strategy (2,124,000 JPY versus 1,629,000
Table 1: Clinical characteristics of examinees in strategies 1 and 2.
Strategy 1
(n = 15,348)
Strategy 2
(n = 5,267,443)
Screening strategy TCS as a primary
screening
FIT as a primary
screening
Sex
Male 5,892 (38.4%) 2,174,604 (41.3%)
Female 9,456 (61.6%) 2,006,926 (38.1%)
Unknown 0 1,085,913 (20.6%)
Age group (yr)
<40 15 (0.1%) 370,750 (7.0%)
40–49 1,918 (12.5%) 870,134 (16.5%)
50–59 4,864 (31.7%) 1,050,813 (19.9%)
60–69 6,521 (42.5%) 1,044,313 (19.8%)
70 2,030 (13.2%) 845,520 (16.1%)
Unknown 0 1,085,913 (20.6%)
Mean (range) 60.1 (40–89) Unknown
JPY). It is assumed that this diﬀerence would have become
even larger if all FIT-positive subjects had then chosen to
have a TCS (2,124,000 JPY versus 1,090,000 JPY). However,
the higher cost associated with the TCS only strategy does
not necessarily deny the cost-eﬀectiveness of this approach
forprimaryscreening.ThisisbecauseTCS,usedasaprimary
screeningstrategy,wasabletoidentifyCRCatanearlierstage
as demonstrated in Table 2, possibly resulting in a decreased
cost of CRC treatment and followup. The clinical course of
the cases of CRC detected in strategy 1 at our institution
is shown in Figure 1. Among the 112 CRC cases identiﬁed,
109 cases followed a clear clinical course, with approximately
80%curedwithasingleendoscopictreatment.Onlyonecase
hashadrecurrentdiseasefollowingtreatment.Suchaclinical
courseindicatesthatearlierdetectionofCRCcanleadtocure
with less invasive treatment, resulting in a shorter period of
followup and decreased cost of CRC care. From this perspec-
tive, it is possible to postulate that the diﬀerence in the cost
of identifying CRC in the two strategies is not as great and
that TCS may be a cost-eﬀective primary screening strategy.
Additionally, we probably underestimated the cost-effective-
ness of TCS because we did not include the possibility to
reduce CRC incidence with TCS in this study. Previous stud-
ies have demonstrated the eﬀect of colonic polypectomy in
reducing CRC incidence [12, 13]. Not only when using TCS
as a primary screening strategy but also when using FIT as
a primary screening, reduction in CRC incidence is expected
[14]. However, taking into account the higher detection rate
for colorectal polyps with TCS and the low rate of under-
going TCS among examinees with a positive FIT, reduction
in CRC incidence is expected more when using TCS as a
primaryscreening.IfweconsiderthiseﬀectofTCS,TCSmay
be a more acceptable choice as a primary screening. Further-
more, considering that using TCS as a primary screening can
lead to better quality of life (QOL) after CRC diagnosis due
to the earlier detection of disease, it is worth performing TCS
as a primary screening of CRC.Gastroenterology Research and Practice 3
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Figure 1: The clinical course of CRC cases detected in strategy 1.
Table 2: Number of CRC cases, the cost to ﬁnd one CRC case, staging of CRC at diagnosis, and initial treatment for CRC in both strategies.
Strategy 1 (n = 15,348) Strategy 2 (n = 5,267,443)
Number of cases of CRC 112 (0.73%) 6,838 (0.13%)
Cost to ﬁnd a case of CRC 2,124,000 JPY 1,629,000 JPY
Staging of CRC at diagnosis
0 81 (72.3%) 1,713 (25.1%)
I 16 (14.3%) 1,043 (15.3%)
II 7 (6.3%) 552 (8.1%)
III a 3 (2.7%) 418 (6.1%)
III b 1 (0.9%) 187 (2.7%)
IV 1 (0.9%) 116 (1.7%)
Unknown 3 (2.7%) 2,809 (41.1%)
Initial treatment for CRC
Endoscopic treatment 93 (83.0%) 2,267 (33.2%)
Surgery 16 (14.3%) 2,466 (36.1%)
No treatment 0 19 (0.3%)
Others 0 67 (1.0%)
Unknown 3 (2.7%) 2,019 (29.5%)
5. Conclusions
The cost associated with identifying one case of CRC is high-
er when using TCS as a primary screening strategy compared
tousing the FIT asa primary screening. However, taking into
account the earlier detection of CRC using TCS, it is possible
to postulate that the ﬁnal cost diﬀerence may be reduced
and that TCS may provide a cost-eﬀective primary screening
strategy. Additionally, considering the eﬀect of TCS on CRC
incidence and a better QOL after earlier detection of CRC
withTCS,TCSisworthusingasaprimaryscreeningofCRC.
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